A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10)

A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10)

<b>Background</b>: V116 is a 21-valent pneumococcal conjugate vaccine (PCV) designed for adults. It contains the most prevalent serotypes associated with invasive pneumococcal disease (IPD) in adults in regions with established pediatric vaccination programs. This Phase 3 study compared...

Full description

Saved in:
Bibliographic Details
Main Authors: Veronika Jotterand, Vinita Jagannath, Andrea Accini Diaz, Juan Diego Velez, Arna Letica, Silvia Narejos Perez, Rebecca Clark, Yoseph Caraco, Olaf Degen, Kyung-Hwa Park, Serhat Ünal, Frederick Wittke, Kimberly Hurtado, Clay Churchill, Ying Zhang, Doreen Fernsler, Jianing Li, Ulrike K. Buchwald, Heather Platt
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Vaccines
Subjects:
pneumococcal conjugate vaccine
serotype
adult
opsonophagocytic activity
invasive pneumococcal disease
Online Access:https://www.mdpi.com/2076-393X/13/4/341
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items